| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Martin-Martin, Natalia |
| dc.contributor.author | Garcia-Longarte, Saioa |
| dc.contributor.author | Lazcano, Uxue |
| dc.contributor.author | Astobiza, Ianire |
| dc.contributor.author | Bozal Basterra, Laura |
| dc.contributor.author | Herranz Martín, Nicolás |
| dc.contributor.author | Salca, Andrei |
| dc.contributor.author | Corres-Mendizabal, Jon |
| dc.contributor.author | Mateo, Joaquin |
| dc.date.accessioned | 2025-08-11T06:29:20Z |
| dc.date.available | 2025-08-11T06:29:20Z |
| dc.date.issued | 2025-06-03 |
| dc.identifier.citation | Martin-Martin N, Garcia-Longarte S, Corres-Mendizabal J, Lazcano U, Astobiza I, Bozal-Basterra L, et al. Transcriptional analysis of metastatic hormone-naïve prostate cancer primary tumor biopsies reveals a relevant role for SOX11 in prostate cancer cell dissemination. Genome Biol. 2025 Jun 3;26:154. |
| dc.identifier.issn | 1474-760X |
| dc.identifier.uri | http://hdl.handle.net/11351/13510 |
| dc.description | Cancer cell reprogramming; Prostate cancer; Single-cell transcriptomics |
| dc.description.abstract | Background: Metastatic hormone-naïve prostate cancer (mHNPC) is an infrequent form of this tumor type that is characterized by metastasis at the time of diagnosis and accounts for up to 50% of prostate cancer-related deaths. Despite the extensive characterization of localized and metastatic castration-resistant prostate cancer, the molecular characteristics of mHNPC remain largely unexplored.
Results: Here, we provide the first extensive transcriptomics characterization of primary tumor specimens from patients with mHNPC. We generate discovery and validation bulk and single-cell RNA-seq datasets and perform integrative computational analysis in combination with experimental studies. Our results provide unprecedented evidence of the distinctive transcriptional profile of mHNPC and identify stroma remodeling as a predominant feature of these tumors. Importantly, we discover a central role for the SRY-box transcription factor 11 (SOX11) in triggering a heterotypic communication that is associated with the acquisition of metastatic properties.
Conclusions: Our study will constitute an invaluable resource for a profound understanding of mHNPC that can influence patient management. |
| dc.language.iso | eng |
| dc.publisher | BMC |
| dc.relation.ispartofseries | Genome Biology;26 |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.source | Scientia |
| dc.subject | Metàstasi |
| dc.subject | Biòpsia |
| dc.subject | Pròstata - Càncer - Aspectes genètics |
| dc.subject | Factors de transcripció |
| dc.subject.mesh | Biopsy |
| dc.subject.mesh | SOXC Transcription Factors |
| dc.subject.mesh | Prostatic Neoplasms |
| dc.subject.mesh | /genetics |
| dc.subject.mesh | Neoplasm Metastasis |
| dc.subject.mesh | Transcriptome |
| dc.title | Transcriptional analysis of metastatic hormone-naïve prostate cancer primary tumor biopsies reveals a relevant role for SOX11 in prostate cancer cell dissemination |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1186/s13059-025-03623-5 |
| dc.subject.decs | biopsia |
| dc.subject.decs | factores de transcripción SOXC |
| dc.subject.decs | neoplasias de la próstata |
| dc.subject.decs | /genética |
| dc.subject.decs | metástasis neoplásica |
| dc.subject.decs | transcriptoma |
| dc.relation.publishversion | https://doi.org/10.1186/s13059-025-03623-5 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Martin-Martin N] Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia, Spain. Centro de Investigación Biomédica En Red de Cáncer (CIBERONC), Madrid, Spain. Traslational Prostate Cancer Research Lab, CIC bioGUNE-Basurto, Biobizkaia Health Research Institute Technology Park, Derio, Spain. [Garcia-Longarte S, Corres-Mendizabal J, Lazcano U, Bozal-Basterra L] Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia, Spain. [Astobiza I] Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia, Spain. Centro de Investigación Biomédica En Red de Cáncer (CIBERONC), Madrid, Spain. [Herranz N, Salca A, Mateo J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain |
| dc.identifier.pmid | 40462200 |
| dc.identifier.wos | 001502167900004 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |